CA
KALV

CoreCap Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

CoreCap Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23
Closed -$280 – 3004
2025
Q3 		$280 Buy
+23
New +$318 ﹤0.01% 2634

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CoreCap Advisors's KALV Position: Q4 2025 in Review

CoreCap Advisors sold out of KalVista Pharmaceuticals (KALV) in Q4 2025, closing a stake of 23 shares — an estimated $280 sold.

CoreCap Advisors first reported a position in KALV in Q3 2025 and held it in 1 quarter. The position peaked at $280 in Q3 2025. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

  • CoreCap Advisors reported no remaining KalVista Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • CoreCap Advisors sold 23 KalVista Pharmaceuticals shares in Q4 2025, an estimated $280.
  • CoreCap Advisors first reported a position in KalVista Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • CoreCap Advisors's KalVista Pharmaceuticals position peaked at $280 in Q3 2025.
  • 161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on CoreCap Advisors's 13F filing for Q4 2025, filed 13 Jan 2026.